benitec biopharma is using patented ‘gene-silencing’ technology to develop drugs for chronic and life-threatening human diseases. our transformational technology, ddrnai, targets and ‘turns off’ specific genes related to disease, providing lasting treatment and potentially cure with a single dose. compared to traditional approaches to rna intereference, ddrnai is easier to deliver, safer to us, more targeted and more efficient. benitec has a pipeline of in-house and partnered drug development programs based on ddrnai, including hepatitis c and b and cancer-associated pain. ddrnai has the potential to silence genes related to thousands of human diseases and is protected by over 40 global patents. the technology is available from benitec under a variety of licence options.
Company profile
Ticker
BNTC
Exchange
Website
CEO
Gregory West
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Benitec Biopharma Proprietary Limited • Benitec Australia Proprietary Limited • Benitec Limited • Benitec, Inc. • RNAi Therapeutics, Inc. • Tacere Therapeutics, Inc. • Benitec, LLC • Benitec IP Holdings, Inc. ...
BNTC stock data
Latest filings (excl ownership)
D
$40.00 mm in equity / options / securities to be acquired, sold $40.00 mm, 17 investors
25 Apr 24
8-K
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
18 Apr 24
8-K
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
18 Apr 24
8-K
Departure of Directors or Certain Officers
8 Mar 24
EFFECT
Notice of effectiveness
6 Mar 24
S-3
Shelf registration
23 Feb 24
8-K
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
13 Feb 24
10-Q
2024 Q2
Quarterly report
13 Feb 24
S-8
Registration of securities for employees
22 Dec 23
8-K
Departure of Directors or Certain Officers
7 Dec 23
Transcripts
Latest ownership filings
3
Aaron Cowen
2 May 24
SC 13D
SUVRETTA CAPITAL MANAGEMENT, LLC
29 Apr 24
SC 13G
HBM Healthcare Investments (Cayman) Ltd.
29 Apr 24
SC 13G
Oliveira Steven Michael
29 Apr 24
SC 13G/A
ADAGE CAPITAL PARTNERS GP, L.L.C.
11 Apr 24
4
Jerel A. Banks
8 Mar 24
4
Megan Boston
8 Mar 24
SC 13G/A
CITADEL ADVISORS LLC
14 Feb 24
SC 13G/A
JANUS HENDERSON GROUP PLC
14 Feb 24
SC 13G/A
SUVRETTA CAPITAL MANAGEMENT, LLC
13 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Jun 23 | Jun 22 | Jun 21 | Jun 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm | 25.88 mm |
Cash burn (monthly) | (no burn) | (no burn) | 1.96 mm | 1.70 mm | 1.53 mm | 1.55 mm |
Cash used (since last report) | n/a | n/a | 14.43 mm | 12.51 mm | 11.24 mm | 11.39 mm |
Cash remaining | n/a | n/a | 11.45 mm | 13.37 mm | 14.64 mm | 14.49 mm |
Runway (months of cash) | n/a | n/a | 5.8 | 7.9 | 9.6 | 9.4 |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 21 |
Opened positions | 1 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 5.56 bn |
Total shares | 14.09 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
BEN Franklin Resources | 10.00 mm | $2.39 bn |
CVI Investments | 1.47 mm | $0.00 |
Oliveira Steven Michael | 1.00 mm | $440.00 k |
Suvretta Capital Management | 769.00 k | $3.12 bn |
Lincoln Park Capital Fund | 423.53 k | $0.00 |
Alpha Capital Anstalt | 124.66 k | $327.00 k |
Vanguard | 74.77 k | $17.83 mm |
VIRT Virtu Financial | 52.87 k | $13.00 k |
Geode Capital Management | 48.22 k | $11.50 mm |
MS Morgan Stanley | 38.60 k | $9.21 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Mar 24 | Jerel A. Banks | Options Common Stock | Grant | Acquire A | No | No | 5.21 | 466,554 | 2.43 mm | 466,554 |
6 Mar 24 | Megan Boston | Options Common Stock | Grant | Acquire A | No | No | 5.21 | 200,004 | 1.04 mm | 200,004 |
6 Dec 23 | Buchi J Kevin | Options Common Stock | Grant | Acquire A | No | No | 3.1301 | 35,000 | 109.55 k | 35,000 |
6 Dec 23 | Smith Edward F | Options Common Stock | Grant | Acquire A | No | No | 3.1301 | 35,000 | 109.55 k | 35,000 |
News
12 Health Care Stocks Moving In Thursday's After-Market Session
18 Apr 24
Why Is Gene Therapy Developer Benitec Biopharma Stock Trading Higher On Thursday?
18 Apr 24
12 Health Care Stocks Moving In Thursday's Intraday Session
18 Apr 24
Market-Moving News for April 18th
18 Apr 24
12 Health Care Stocks Moving In Thursday's Pre-Market Session
18 Apr 24